Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

AbbVie, building out its post-Humira future, posts 5 late-stage trial wins for Skyrizi and Rinvoq
Fierce Pharma
Wed, 05/26/21 - 12:05 pm
Tags:
AbbVie, Humira, drug pricing, patents, immunology, Skyrizi, Rinvoq, clinical trials, Crohn's Disease, atopic dermatitis
Lilly leads the big pharma pack on pipeline value
EP Vantage
Tue, 05/25/21 - 11:04 am
Tags:
Eli Lilly, diabetes, Alzheimer's disease, GSK, AbbVie
AbbVie’s last stand: How an Icelandic billionaire’s biosimilar has one final shot to dethrone Humira
Endpoints
Mon, 05/24/21 - 11:30 pm
Tags:
AbbVie, biosimilars, Humira, Alvotech
Humira patents take center stage as House panel targets AbbVie pricing
BioPharma Dive
Tue, 05/18/21 - 11:23 pm
Tags:
AbbVie, Humira, drug pricing
Alvotech, not content to line up behind other Humira biosims, sues AbbVie over 'wrongful monopoly'
Fierce Pharma
Tue, 05/11/21 - 10:23 pm
Tags:
AbbVie, patents, biosimilars, Humira, Alvotech
An AbbVie clinical vet heading early oncology jumps ship to build his own team at NK cell-focused biotech
Endpoints
Tue, 05/11/21 - 11:10 am
Tags:
Thorsten Graef, Pharmacyclics, AbbVie, oncology, Acepodia, NK cells
AbbVie makes a hefty play to boost aesthetics business, paying $550M for non-invasive body sculpting device
Endpoints
Mon, 05/10/21 - 09:37 am
Tags:
AbbVie, Allergan Aesthetics, M&A, Soliton and Resonic
AbbVie's Humira regains top pharma TV spender spot, while sibling brands Rinvoq and Skyrizi tag along
Fierce Pharma
Wed, 05/5/21 - 10:50 am
Tags:
AbbVie, Humira, DTC advertising, television ads, Sanofi, Dupixent, Novo Nordisk, Rybelsus
This Is Why Humira Isn't AbbVie's Biggest Problem Right Now
Motley Fool
Mon, 05/3/21 - 10:55 am
Tags:
AbbVie, Humira, patents, patent cliff, Imbruvica
Capsida unveils $140M, AbbVie alliance & tech that takes gene therapy to the brain
MedCity News
Sun, 05/2/21 - 10:25 pm
Tags:
Capsida Biotherapeutics, funding, AbbVie
AbbVie Rises on Q1 Beats, Raised EPS Guidance
Motley Fool
Sat, 05/1/21 - 09:21 pm
Tags:
AbbVie, earnings
The retreat of corporate venture funding?
EP Vantage
Fri, 04/23/21 - 11:02 am
Tags:
funding, venture funding, venture capital, AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GSK, JNJ, Merck, Merck KGaA, Pfizer, Roche, Sanofi, Takeda
AbbVie's Rinvoq rollout on track despite JAK safety concerns, but uncertainty remains: analyst
Fierce Pharma
Thu, 04/22/21 - 11:42 pm
Tags:
AbbVie, Rinvoq, Xeljanz, FDA, rheumatoid arthritis
Johnson & Johnson, AbbVie, Teva and Endo to face pharma's first opioid trial since 2019
Fierce Pharma
Mon, 04/19/21 - 12:13 pm
Tags:
JNJ, AbbVie, Allergan, Teva Pharmaceutical, Endo, opioids, opioid crisis
Big pharma freshens up
EP Vantage
Fri, 04/9/21 - 10:35 am
Tags:
Merck, Bristol Myers Squibb, Astellas, Novo Nordisk, AbbVie, Sanofi
Series of JAK inhibitor delays may signal an upcoming FDA adcomm
Endpoints
Thu, 04/8/21 - 11:10 am
Tags:
FDA, JAK inhibitors, AbbVie, Rinvoq, Pfizer, Xeljanz, Eli Lilly, olumiant
AbbVie presents applications to FDA and EMA for approval of SKYRIZI in psoriatic arthritis
Pharmaceutical Business Review
Thu, 04/8/21 - 10:22 am
Tags:
AbbVie, Skyrizi, FDA, EMA, psoriatic arthritis
AbbVie's Rinvoq expansion hits a 2nd snag as FDA delays $2B atopic dermatitis ruling
Fierce Pharma
Mon, 04/5/21 - 02:47 pm
Tags:
AbbVie, Rinvoq, Humra, FDA
AbbVie Receives NDA for Atogepant, Aims to Stop Migraines in Their Tracks
BioSpace
Wed, 03/31/21 - 10:58 pm
Tags:
AbbVie, atogepant, migraines, FDA
AbbVie accuses rival of stealing blockbuster ‘trade secrets’ as clock ticks down on biosimilar assault
Endpoints
Wed, 03/24/21 - 10:23 am
Tags:
AbbVie, Humira, trade secrets, Alvotech

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.